 Stockopedia |
Skyepharma slides as US group ends asthma drug deal
The Guardian Shares in Skyepharma have fallen around 5% after another setback for its asthma treatment flutiform. The company has announced that Abbott Laboratories has … SkyePharma loses US partner Abbot shelves interest in SkyePharma's Flutiform SkyePharma says Abbott ends US Flutiform deal |
View full post on asthma – Google News